Pulse Biosciences Inc. has announced that its nPulse™ Cardiac Catheter, utilizing proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, will be featured in multiple presentations at the upcoming 31st Annual AF Symposium, scheduled for February 5-7, 2026, in Boston, Massachusetts. The company plans to present 6-month and 12-month follow-up data from its Cardiac Catheter Human Feasibility Study in Europe, reviewing outcomes from the first 150 patients treated with the nPulse Cardiac Catheter at three European centers. Additionally, a preclinical study comparing the depth of cardiac lesions produced by nanosecond versus microsecond pulses will be presented. A live case transmission from Na Homolce Hospital in Prague will also demonstrate the device's workflow efficiency and integration with Abbott's EnSiteX™ 3D Mapping System. These results are scheduled to be presented at the symposium and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203979934) on February 03, 2026, and is solely responsible for the information contained therein.